MDXG$5.75
Chart
Performance
Key Stats
AI MDXG Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyMiMedx Group shows strong fundamental performance with good growth potential and a healthy balance sheet. Technicals indicate a bullish trend, but some indicators suggest a possible short-term pullback. Thematic alignment is moderate.
Thematic
MiMedx operates in the healthcare sector, specifically focusing on regenerative medicine and wound care. While there are positive long-term trends in healthcare innovation and aging populations, its specific market positioning and the company's growth trajectory suggest a neutral thematic outlook.
Fundamental
MiMedx exhibits strong revenue growth and improved profitability, coupled with a healthy balance sheet and positive free cash flow. Valuation metrics are reasonable given the growth, but slightly elevated compared to historical performance.
Technical
The stock shows a generally bullish trend, with multiple moving averages indicating buying pressure. However, some oscillators suggest the stock may be approaching overbought territory, hinting at potential consolidation or a minor pullback.
| Factor | Score |
|---|---|
| Healthcare Innovation | 70 |
| Aging Population & Chronic Diseases | 65 |
| Regulatory Environment (Healthcare) | 40 |
| Competition in Regenerative Medicine | 50 |
| Market Adoption of Allografts | 50 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 75 |
| Growth | 70 |
| Balance Sheet Health | 85 |
| Cash Flow | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 55 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Market Sentiment | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprise
The company has exceeded earnings per share (EPS) estimates in 5 out of the last 8 reported quarters, with a notable surprise of 55.56% in Q3 2024 and 357.14% in Q1 2024.
Improving Cash Position
Cash equivalents have increased from $65.95M in Q4 2022 to $104.416M in Q4 2024, indicating improved liquidity and financial stability.
Bearish Points (7)
Negative Net Margin in Prior Years
The company reported negative net margins in 2021 (-5.1%) and 2022 (-11.3%), indicating past periods of unprofitability, although recent years show improvement.
Inconsistent Quarterly Revenue Growth
Quarterly revenue shows fluctuations, with Q4 2024 revenue ($92.907M) lower than Q1 2025 ($88.205M reported in Q1 2025 data) and Q4 2024 ($92.907M) being lower than Q1 2024 ($84.709M) if looking at the quarterly income statement, suggesting potential volatility in top-line performance.
Calendar
July 2025
31
Next Earnings Date
H: $0.06
A: $0.06
L: $0.05
H: 92.00M
A: 90.79M
L: 89.28M
Profile
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Seasonals
Price Target
12.00 USD
The 39 analysts offering 1 year price forecasts for MDXG have a max estimate of 13.00 and a min estimate of 11.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in non-invasive cancer diagnostics, particularly for colorectal and breast cancer, similar to MDXG's focus on prostate cancer diagnostics.
Weight: 95
Leading company in liquid biopsy for cancer detection, recurrence monitoring, and treatment selection, a highly complementary field to MDXG's molecular diagnostics.
Weight: 93
Offers a broad portfolio of molecular diagnostic tests, including Signatera for cancer, which focuses on minimal residual disease (MRD) detection in oncology.
Weight: 90
Specializes in oncology testing services, providing a wide range of molecular, genomic, and pathology testing solutions for cancer diagnosis and treatment.